Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
Status:
Completed
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and
pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product
comprised of the drug component OLZ administered by a Precision Olfactory Delivery (POD®)
nasal spray device (I231 POD® Device). The proposed indication for INP105 is the treatment of
acute agitation associated with schizophrenia and bipolar I disorder.